Clinicopathological characteristics and prognostic outcome of 30 patients with breast cancer during pregnancy

MA Jun-ren; LIU Ya-xuan; LIU Hai-yan; LU Cheng-qiu; WU Ke-jin

doi:10.19538/j.cjps.issn1005-2208.2025.02.15

Abstract：Objective To analyze the clinicopathological features,prognosis and pregnancy-related outcomes of patients with breast cancer during pregnancy.Methods Clinical and pathological data of 30 patients with breast cancer in pregnancy admitted to the Obstetrics and Gynecology Hospital of Fudan University from January 2016 to December 2023 were retrospectively analyzed,including baseline data,treatment modalities,pathological data,pregnancy and offspring-related outcomes and tumor prognosis.The log-rank test was used to analyze the impacting factors of disease-free survival(DFS)and overall survival(OS).Results The median age of the patients was 35(26-46)years,the median gestational week at the time of diagnosis was 26+3(15-36)week of pregnancy,and 66.7％of the patients had a previous reproductive history.There were 24 patients with AJCC stage 0-Ⅱ and 6 patients with AJCC stage Ⅲ.25 patients underwent surgery,and 24 patients received chemotherapy during pregnancy.2 patients chose induced labour,13 patients had preterm labour and the remaining 15 patients full-term labour.1 case of ventricular septal defect,1 case of hyperbilirubinaemia in the neonate and 8 cases of low birth weight babies were followed up with good development.The median follow-up was about 54 months,and the 5-year DFS and OS rates were 90％and 93.3％,respectively.The cumulative DFS rate(x2=13.501,P＜0.01)and cumulative OS rate(x2=7.370,P＜0.01)of AJCC stage 0-Ⅱ patients were higher than those of stage Ⅲ patients,and the cumulative DFS rate of multiparous women(x2=5.797,P=0.016)was higher than that of primiparous women,and the difference was statistically significant.Conclusions Patients with breast cancer during pregnancy who receive standardized treatment do not have adverse pregnancy outcomes or offspring outcomes,and clinical stage is an important factor influencing the long-term prognosis of patients with breast cancer during pregnancy.